How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about olaparib

Marketing authorisation indication

2.1 Olaparib (Lynparza, AstraZeneca) with bevacizumab (Avastin, Roche) is indicated for 'maintenance treatment of adult patients with advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency positive status defined by either a BRCA1/2 mutation and/or genomic instability'.

Dosage in the marketing authorisation

2.2 The dosage schedules are available in the summary of product characteristics for olaparib and the summary of product characteristics for bevacizumab.

Price

2.3 The list price for olaparib tablets is £2,317.50 per 14-day pack (56 150-mg tablets); £4,635.00 per 28-day cycle (excluding VAT; BNF online, accessed May 2023).

2.4 The company has a commercial arrangement. This makes olaparib with bevacizumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.